In summary, our findings highlight that combination therapy involving liposomal MMP3-siRNA and cisplatin effectively mitigates tumor growth in a cisplatin-resistant mouse model of HGSOC but raises concerns about the feasibility of targeting MMP3 alone in patients with ovarian cancer. Here, MMP3 is linked to ovarian cancer.